DW-MSC [mesenchymal stem cell] is under development as a drug for intractable and rare diseases and degenerative diseases as well as a genetic delivery platform to strengthen stem cell functions. As a stem cell therapy, DW-MSC is being developed with indications for acute pancreatitis, stroke, dementia, cerebral atrophy, and idiopathic pulmonary fibrosis. ‘DW-MSC’ is the 1st mass production available stem cell line developed in Korea which has a high competitiveness for commercialization. Daewoong aims to develop a best-in-class stem cell therapy by applying Cell & Gene technologies to optimize its functions under the name of “Smart Stem Cell”

Daewoong Pharmaceutical is continuously developing new products of 2-in-1, 3-in-1, 4-in-1 combination drugs, multi-delivery sustained release oral forms and long-acting depot injections by using a platform technology (oral dosage forms such as core tablets, multi-layer tablets, multi-filling capsules, and long acting depot injections based on microsphere/nano technology). We, also, are working on life cycle extension of key products that form the brand image of Daewoong Pharmaceutical.